Janux Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Janux Therapeutics has a total shareholder equity of $656.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $695.0M and $38.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$658.03m |
| Equity | US$656.10m |
| Total liabilities | US$38.92m |
| Total assets | US$695.02m |
Recent financial health updates
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20Recent updates
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01Janux Therapeutics: Buoyed By Buyout Speculation
Sep 01Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Financial Position Analysis
Short Term Liabilities: JANX's short term assets ($666.3M) exceed its short term liabilities ($17.2M).
Long Term Liabilities: JANX's short term assets ($666.3M) exceed its long term liabilities ($21.7M).
Debt to Equity History and Analysis
Debt Level: JANX is debt free.
Reducing Debt: JANX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JANX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: JANX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 41.1% each year